Search

Your search keyword '"Vidriales, María B."' showing total 12 results
Start Over Author "Vidriales, María B." Search Limiters Full Text
12 results on '"Vidriales, María B."'

1. Baseline immunophenotypic profile of bone marrow leukemia cells in acute myeloid leukemia with nucleophosmin-1 gene mutation: a EuroFlow study

Author

Matarraz, Sergio, Leoz, Pilar, Yeguas-Bermejo, Ana, van der Velden, Vincent, Bras, Anne E., Sánchez Gallego, Jose I., Lecrevisse, Quentin, Ayala-Bueno, Rosa, Teodosio, Cristina, Criado, Ignacio, González-González, María, Flores-Montero, Juan, Avendaño, Alejandro, Vidriales, María B., Chillón, María C., González, Teresa, García-Sanz, Ramón, Prieto Conde, María I., Villamor, Neus, Magnano, Laura, Colado, Enrique, Fernández, Paula, Sonneveld, Edwin, Philippé, Jan, Reiterová, Michaela, Caballero Berrocal, Juan C., Diaz-Gálvez, Francisco J., Ramos, Fernando, Dávila Valls, Julio, Manjón Sánchez, Raquel, Solano Tovar, Jackeline, Calvo, Xavier, García Alonso, Luis, Arenillas, Leonor, Alonso, Sara, Fonseca, Ariana, Quirós Caso, Covadonga, van Dongen, Jacques J. M., and Orfao, Alberto

Published
2023
Full Text
View/download PDF

2. Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens

Author

Castaño-Bonilla, Tamara, Alonso-Dominguez, Juan M., Barragán, Eva, Rodríguez-Veiga, Rebeca, Sargas, Claudia, Gil, Cristina, Chillón, Carmen, Vidriales, María B., García, Raimundo, Martínez-López, Joaquín, Ayala, Rosa, Larrayoz, María J., Anguita, Eduardo, Cuello, Rebeca, Cantalapiedra, Alberto, Carrillo, Estrella, Soria-Saldise, Elena, Labrador, Jorge, Recio, Isabel, Algarra, Lorenzo, Rodríguez-Medina, Carlos, Bilbao-Syeiro, Cristina, López-López, Juan A., Serrano, Josefina, De Cabo, Erik, Sayas, María J., Olave, María T., Sánchez-García, Joaquín, Mateos, Mamen, Blas, Carlos, López-Lorenzo, Jose L., Lainez-Gonzalez, Daniel, Serrano, Juana, Martínez-Cuadrón, David, Sanz, Miguel A., and Montesinos, Pau

Published
2021
Full Text
View/download PDF

3. Baseline immunophenotypic profile of bone marrow leukemia cells in acute myeloid leukemia with nucleophosmin-1 gene mutation:a EuroFlow study

Author

Matarraz, Sergio, Leoz, Pilar, Yeguas-Bermejo, Ana, van der Velden, Vincent, Bras, Anne E., Sánchez Gallego, Jose I., Lecrevisse, Quentin, Ayala-Bueno, Rosa, Teodosio, Cristina, Criado, Ignacio, González-González, María, Flores-Montero, Juan, Avendaño, Alejandro, Vidriales, María B., Chillón, María C., González, Teresa, García-Sanz, Ramón, Prieto Conde, María I., Villamor, Neus, Magnano, Laura, Colado, Enrique, Fernández, Paula, Sonneveld, Edwin, Philippé, Jan, Reiterová, Michaela, Caballero Berrocal, Juan C., Diaz-Gálvez, Francisco J., Ramos, Fernando, Dávila Valls, Julio, Manjón Sánchez, Raquel, Solano Tovar, Jackeline, Calvo, Xavier, García Alonso, Luis, Arenillas, Leonor, Alonso, Sara, Fonseca, Ariana, Quirós Caso, Covadonga, van Dongen, Jacques J.M., Orfao, Alberto, Matarraz, Sergio, Leoz, Pilar, Yeguas-Bermejo, Ana, van der Velden, Vincent, Bras, Anne E., Sánchez Gallego, Jose I., Lecrevisse, Quentin, Ayala-Bueno, Rosa, Teodosio, Cristina, Criado, Ignacio, González-González, María, Flores-Montero, Juan, Avendaño, Alejandro, Vidriales, María B., Chillón, María C., González, Teresa, García-Sanz, Ramón, Prieto Conde, María I., Villamor, Neus, Magnano, Laura, Colado, Enrique, Fernández, Paula, Sonneveld, Edwin, Philippé, Jan, Reiterová, Michaela, Caballero Berrocal, Juan C., Diaz-Gálvez, Francisco J., Ramos, Fernando, Dávila Valls, Julio, Manjón Sánchez, Raquel, Solano Tovar, Jackeline, Calvo, Xavier, García Alonso, Luis, Arenillas, Leonor, Alonso, Sara, Fonseca, Ariana, Quirós Caso, Covadonga, van Dongen, Jacques J.M., and Orfao, Alberto

Published
2023

4. Outcomes after intensive chemotherapy for secondary and myeloidrelated changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry

Author

Martínez-Cuadrón, David, primary, Megías-Vericat, Juan E., additional, Gil, Cristina, additional, Bernal, Teresa, additional, Tormo, Mar, additional, Martínez-Sánchez, Pilar, additional, Rodríguez-Medina, Carlos, additional, Serrano, Josefina, additional, Herrera, Pilar, additional, Simón, José A. Pérez, additional, Sayas, María J., additional, Bergua, Juan, additional, Lavilla-Rubira, Esperanza, additional, Amigo, Maria Luz, additional, Benavente, Celina, additional, Lorenzo, Jose L. López, additional, Pérez-Encinas, Manuel M., additional, Vidriales, María B., additional, Colorado, Mercedes, additional, De Rueda, Beatriz, additional, García-Boyero, Raimundo, additional, Marini, Sandra, additional, García-Suárez, Julio, additional, López-Pavía, María, additional, Gómez-Roncero, Maria I., additional, Noriega, Víctor, additional, López, Aurelio, additional, Labrador, Jorge, additional, Cabello, Ana, additional, Sossa, Claudia, additional, Algarra, Lorenzo, additional, Stevenazzi, Mariana, additional, Solana-Altabella, Antonio, additional, Boluda, Blanca, additional, and Montesinos, Pau, additional

Published
2023
Full Text
View/download PDF

5. Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia

Author

Martínez Cuadrón, David, Serrano, Josefina, Mariz, José, Gil, Cristina, Tormo, Mar, Martínez Sánchez, María Del Pilar, Rodríguez Arbolí, Eduardo, García Boyero, Raimundo, Rodríguez Medina, Carlos, Martínez Chamorro, Carmen, Polo, Marta, Bergua, Juan, Aguiar, Eliana, Amigo, María L., Herrera, Pilar, Alonso Domínguez, Juan Manuel, Bernal, Teresa, Espadana, Ana, Sayas, María J., Algarra, Lorenzo, Vidriales, María B., Vasconcelos, Graça, Vives, Susana, Pérez Encinas, Manuel M., López, Aurelio, Noriega Concepción, Víctor, García Fortes, María, Chillón, María C., Rodríguez Gutiérrez, Juan I., Calasanz, María J., Labrador, Jorge, López, Juan A., Boluda, Blanca, Rodríguez Veiga, Rebeca, Martínez López, Joaquín, Barragán, Eva, Sanz, Miguel A., Montesinos, Pau, Martínez Cuadrón, David, Serrano, Josefina, Mariz, José, Gil, Cristina, Tormo, Mar, Martínez Sánchez, María Del Pilar, Rodríguez Arbolí, Eduardo, García Boyero, Raimundo, Rodríguez Medina, Carlos, Martínez Chamorro, Carmen, Polo, Marta, Bergua, Juan, Aguiar, Eliana, Amigo, María L., Herrera, Pilar, Alonso Domínguez, Juan Manuel, Bernal, Teresa, Espadana, Ana, Sayas, María J., Algarra, Lorenzo, Vidriales, María B., Vasconcelos, Graça, Vives, Susana, Pérez Encinas, Manuel M., López, Aurelio, Noriega Concepción, Víctor, García Fortes, María, Chillón, María C., Rodríguez Gutiérrez, Juan I., Calasanz, María J., Labrador, Jorge, López, Juan A., Boluda, Blanca, Rodríguez Veiga, Rebeca, Martínez López, Joaquín, Barragán, Eva, Sanz, Miguel A., and Montesinos, Pau

Abstract

This retrospective study investigated outcomes of 404 patients with relapsed/refractory (R/R) FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) acute myeloid leukemia (AML) enrolled in the PETHEMA registry, pre-approval of tyrosine kinase inhibitors. Most patients (63%) had received first-line intensive therapy with 3 + 7. Subsequently, patients received salvage with intensive therapy (n = 261), non-intensive therapy (n = 63) or supportive care only (n = 80). Active salvage therapy (i.e., intensive or non-intensive therapy) resulted in a complete remission (CR) or CR without hematological recovery (CRi) rate of 42%. More patients achieved a CR/CRi with intensive (48%) compared with non-intensive (19%) salvage therapy (p < 0.001). In the overall population, median overall survival (OS) was 5.5 months; 1- and 5-year OS rates were 25% and 7%. OS was significantly (p < 0.001) prolonged with intensive or non-intensive salvage therapy compared with supportive therapy, and in those achieving CR/CRi versus no responders. Of 280 evaluable patients, 61 (22%) had an allogeneic stem-cell transplant after they had achieved CR/CRi. In conclusion, in this large cohort study, salvage treatment approaches for patients with FLT3-ITD mutated R/R AML were heterogeneous. Median OS was poor with both non-intensive and intensive salvage therapy, with best long-term outcomes obtained in patients who achieved CR/CRi and subsequently underwent allogeneic stem-cell transplant., Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Depto. de Medicina, Fac. de Medicina, TRUE, pub

Published
2022

7. Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia

Author

Santamaría, Carlos M., Chillón, María C., García-Sanz, Ramón, Pérez, Cristina, Caballero, María D., Ramos, Fernando, de Coca, Alfonso García, Alonso, José M., Giraldo, Pilar, Bernal, Teresa, Queizán, José A., Rodriguez, Juan N., Fernández-Abellán, Pascual, Bárez, Abelardo, Peñarrubia, María J., Balanzategui, Ana, Vidriales, María B., Sarasquete, María E., Alcoceba, Miguel, Díaz-Mediavilla, Joaquín, San Miguel, Jesús F., and Gonzalez, Marcos

Published
2009
Full Text
View/download PDF

11. Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry.

Author

Martínez-Cuadrón D, Megías-Vericat JE, Gil C, Bernal T, Tormo M, Martínez-Sánchez P, Rodríguez-Medina C, Serrano J, Herrera P, Simón JAP, Sayas MJ, Bergua J, Lavilla-Rubira E, Amigo ML, Benavente C, Lorenzo JLL, Pérez-Encinas MM, Vidriales MB, Colorado M, De Rueda B, García-Boyero R, Marini S, García-Suárez J, López-Pavía M, Gómez-Roncero MI, Noriega V, López A, Labrador J, Cabello A, Sossa C, Algarra L, Stevenazzi M, Solana-Altabella A, Boluda B, and Montesinos P

Subjects
Humans, Middle Aged, Aged, Retrospective Studies, Disease-Free Survival, Cytarabine, Remission Induction, Leukemia, Myeloid, Acute diagnosis, Leukemia, Myeloid, Acute drug therapy, Hematopoietic Stem Cell Transplantation
Abstract

Treatment options for patients with secondary acute myeloid leukemia (sAML) and AML with myeloid-related changes (AMLMRC) aged 60 to 75 years are scarce and unsuitable. A pivotal trial showed that CPX-351 improved complete remission with/without incomplete recovery (CR/CRi) and overall survival (OS) as compared with standard "3+7" regimens. We retrospectively analyze outcomes of 765 patients with sAML and AML-MRC aged 60 to 75 years treated with intensive chemotherapy, reported to the PETHEMA registry before CPX-351 became available. The CR/CRi rate was 48%, median OS was 7.6 months (95% confidence interval [CI]: 6.7-8.5) and event-free survival (EFS) 2.7 months (95% CI: 2-3.3), without differences between intensive chemotherapy regimens and AML type. Multivariate analyses identified age ≥70 years, Eastern Cooperative Oncology Group performance status ≥1 as independent adverse prognostic factors for CR/CRi and OS, while favorable/intermediate cytogenetic risk and NPM1 were favorable prognostic factors. Patients receiving allogeneic stem cell transplant (HSCT), autologous HSCT, and those who completed more consolidation cycles showed improved OS. This large study suggests that classical intensive chemotherapy could lead to similar CR/CRi rates with slightly shorter median OS than CPX-351.

Published
2024
Full Text
View/download PDF

12. Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3 -ITD Mutation-Positive Acute Myeloid Leukemia.

Author

Martínez-Cuadrón D, Serrano J, Mariz J, Gil C, Tormo M, Martínez-Sánchez P, Rodríguez-Arbolí E, García-Boyero R, Rodríguez-Medina C, Martínez-Chamorro C, Polo M, Bergua J, Aguiar E, Amigo ML, Herrera P, Alonso-Domínguez JM, Bernal T, Espadana A, Sayas MJ, Algarra L, Vidriales MB, Vasconcelos G, Vives S, Pérez-Encinas MM, López A, Noriega V, García-Fortes M, Chillón MC, Rodríguez-Gutiérrez JI, Calasanz MJ, Labrador J, López JA, Boluda B, Rodríguez-Veiga R, Martínez-López J, Barragán E, Sanz MA, Montesinos P, and On Behalf Of The Pethema Group

Abstract

This retrospective study investigated outcomes of 404 patients with relapsed/refractory (R/R) FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) acute myeloid leukemia (AML) enrolled in the PETHEMA registry, pre-approval of tyrosine kinase inhibitors. Most patients (63%) had received first-line intensive therapy with 3 + 7. Subsequently, patients received salvage with intensive therapy (n = 261), non-intensive therapy (n = 63) or supportive care only (n = 80). Active salvage therapy (i.e., intensive or non-intensive therapy) resulted in a complete remission (CR) or CR without hematological recovery (CRi) rate of 42%. More patients achieved a CR/CRi with intensive (48%) compared with non-intensive (19%) salvage therapy (p < 0.001). In the overall population, median overall survival (OS) was 5.5 months; 1- and 5-year OS rates were 25% and 7%. OS was significantly (p < 0.001) prolonged with intensive or non-intensive salvage therapy compared with supportive therapy, and in those achieving CR/CRi versus no responders. Of 280 evaluable patients, 61 (22%) had an allogeneic stem-cell transplant after they had achieved CR/CRi. In conclusion, in this large cohort study, salvage treatment approaches for patients with FLT3-ITD mutated R/R AML were heterogeneous. Median OS was poor with both non-intensive and intensive salvage therapy, with best long-term outcomes obtained in patients who achieved CR/CRi and subsequently underwent allogeneic stem-cell transplant.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results